Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer ...

Foghorn Therapeutics ( ($FHTX) ) has issued an announcement. In November 2025, Foghorn Therapeutics presented its strategic advancements, ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago. These ...

Foghorn Therapeutics (FHTX) posted another year of rising losses, with annual net losses increasing at a rate of 1.4% over the past five years and no positive EPS expected in the next three years.

Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid ...

A webcast of the available presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 90 days.

Foghorn Therapeutics, a biotech whose technology can affect one of the ways a cell regulates gene expression, has shown its approach has the potential to address a particular mutation tied to more ...

A patient has died in a clinical trial testing a Foghorn Therapeutics drug candidate for blood cancer, leading the FDA to pause enrollment of new patients in the study. Circumstances of the death are ...

Clickers gonna click. Despite mandatory corporate training, general security awareness, and constant harping about the risks of clicking on unverified links in e-mails and other documents, people have ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--FogHorn, a leading developer of edge computing AI software for industrial and commercial Internet of Things (IoT) solutions, today announced plans to collaborate ...